Clinical Trials Logo

Clinical Trial Summary

This clinical trial improves an existing pain management program and tests its effect on head and neck cancer survivors. This trial aims to find a better program to improve pain-related physical functioning, mood, and quality of life in a sample of individuals who have undergone treatment for head and neck cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Adapt an existing telehealth pain management intervention to target improvement of pain-related physical functioning, mood, substance use, and quality of life in a local sample of veteran head and neck cancer (HNC) survivors. II. Conduct a pilot of the adapted intervention to examine the feasibility (accrual, adherence, attrition) and acceptability (participant satisfaction) that will form the basis of a well-powered, randomized clinical trial submitted for funding to the National Institutes of Health (NIH), American Cancer Society (ACS), or Veterans Affairs (VA). OUTLINE: Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks. After completion of study, patients are followed up at 2 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05115825
Study type Interventional
Source OHSU Knight Cancer Institute
Contact
Status Recruiting
Phase N/A
Start date March 27, 2019
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04110249 - Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer N/A
Completed NCT01831089 - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Phase 1
Completed NCT03663985 - FALCOn (Facteur AnthropoLogique Cancer Orl)
Recruiting NCT05077072 - Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients Phase 2
Recruiting NCT04151082 - High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors Phase 1/Phase 2
Completed NCT03964896 - Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02474095 - Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer N/A
Withdrawn NCT03261180 - Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer N/A
Recruiting NCT04618432 - Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Active, not recruiting NCT02615275 - Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy Early Phase 1
Recruiting NCT04475640 - Cancer Genetic Testing in Ethnic Populations
Not yet recruiting NCT05018208 - Remote Monitoring in Cancer Care: A Platform Study
Recruiting NCT00991094 - Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Recruiting NCT04870762 - Customized 3D Printed Oral Stents During Head and Neck Radiotherapy N/A
Completed NCT02369835 - Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Phase 3
Active, not recruiting NCT03902535 - Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
Recruiting NCT03795610 - Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT04788264 - Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment N/A
Active, not recruiting NCT02718820 - Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2